Provided by Tiger Trade Technology Pte. Ltd.

Armata Pharmaceuticals, Inc.

5.10
+0.680015.38%
Post-market: 5.100.00000.00%19:30 EDT
Volume:111.49K
Turnover:535.48K
Market Cap:189.63M
PE:-0.97
High:5.10
Open:4.42
Low:4.42
Close:4.42
52wk High:16.34
52wk Low:2.40
Shares:37.18M
Float Shares:11.88M
Volume Ratio:1.06
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2744
EPS(LYR):-4.8000
ROE:-3439.35%
ROA:-25.83%
PB:-0.82
PE(LYR):-1.06

Loading ...

Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate

Benzinga Earnings
·
Aug 13

Armata Swings to FY26 Q2 Net Income of $74.14 Million; Operating Loss Widens to $10.31 Million

Reuters
·
Aug 13

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

THOMSON REUTERS
·
Aug 13

Armata Pharmaceuticals, - Promotes David House to Chief Financial Officer

THOMSON REUTERS
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP)

TIPRANKS
·
Jul 20

Armata Pharmaceuticals - Appoints David House as Chief Financial Officer Effective July 17, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 20

Armata provides update on AP-SA02 studies

TIPRANKS
·
Jul 20

Armata Pharmaceuticals Names David House CFO

Reuters
·
Jul 20

Armata Pharmaceuticals Announces Press Release Availability

Reuters
·
Jul 13

Armata Wins FDA Agreement on Pediatric Study Plan for Ap-sa02 in Complicated S. Aureus Bacteremia

Reuters
·
Jul 13

Armata Pharmaceuticals - Adult Phase 3 Study for Ap-sa02 Expected to Initiate in Second Half of 2026

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for Ap-sa02 for the Treatment of Complicated Staphylococcus Aureus Bacteremia

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals - FDA Defers Pediatric Studies for Ap-sa02 Until Adult Phase 3 Data Generated

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals - FDA Agreement Establishes Regulatory Framework for Ap-sa02 in Pediatric SAB

THOMSON REUTERS
·
Jul 13

Armata Pharma Amends 8-K to Disclose Director Daniel Gilmer Committee Assignment

Reuters
·
Jun 25

Sector Update: Healthcare Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Jun 23

Armata Pharmaceuticals Shares Rise on Additional $2.5M Government Grant

Dow Jones
·
Jun 23

Armata Pharmaceuticals receives additional USD 2.5 million DoD funding for AP-SA02 program

Reuters
·
Jun 23

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding From the U.S. Department of Defense to Support AP-Sa02

THOMSON REUTERS
·
Jun 23

Armata Pharmaceuticals shareholders elect seven directors at annual meeting

Reuters
·
Jun 17